معرفی
Daniel O'Neill is a cancer research specialist at Newcastle University, focusing on molecular mechanisms in hormone-driven malignancies. His work centers on androgen receptor (AR) and estrogen receptor (ER) signaling pathways, with significant contributions to understanding prostate and breast cancer biology through collaborations with leading researchers including Professor Craig Robson and Dr. Luke Gaughan.
His research interests span molecular oncology, epigenetic regulation, and therapeutic targeting of receptor signaling. Key areas include:
- AR/ER co-regulator identification (Usp12, KDM4B, SETD6)
- Post-translational modifications in cancer progression
- Apoptosis induction mechanisms in therapy-resistant tumors
- Epigenetic control of hormone-responsive gene networks
Analysis of his 2013-2016 publications reveals consistent focus on receptor stability mechanisms. His work demonstrates how deubiquitination (Usp12), demethylation (KDM4B), and methyltransferase activity (SETD6) govern receptor turnover and transcriptional output, establishing critical links between molecular modifications and cancer cell survival.
No scientific awards were documented in the source material.
O'Neill operates within Newcastle University's collaborative cancer research framework without indication of independent grant leadership or student supervision in the available records. His publications suggest integration into larger research teams investigating receptor signaling pathways, with emphasis on translational molecular oncology.
While no dedicated laboratory is referenced, his work aligns with Newcastle's cancer biology initiatives, particularly in prostate cancer research where he contributed to key studies on AR regulation and therapeutic targeting mechanisms.